Publication Name	World Journal of Gastroenterology
Manuscript ID	8261
Country	United States

Received	2013-12-22 15:15
Peer-Review Started	2013-12-22 23:10
To Make the First Decision	2014-01-09 19:05
Return for Revision	2014-01-20 12:00
Revised	2014-02-15 04:47
Second Decision	2014-05-19 11:06
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-05-19 11:12
Articles in Press	2014-05-23 09:43
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-09-24 16:55
Publish the Manuscript Online	2014-10-16 15:53

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Topic Highlights
Article Title	Medical management of gastric cancer: A 2014 update
Manuscript Source	Invited Manuscript
All Author List	Elena Elimova, Hironori Shiozaki, Roopma Wadhwa, Kazuki Sudo, Qiongrong Chen, Jeannelyn S Estrella, Mariela A Blum, Brian Badgwell, Prajnan Das, Shumei Song and Jaffer A Ajani
Funding Agency and Grant Number
Corresponding Author	Jaffer A Ajani, MD, Department of Gastrointestinal Medical Oncology, University of Texas, Anderson Cancer Center, 1515 Holcombe Blvd, (FC10.3022), Houston, TX 77030, United States. jajani@mdanderson.org
Key Words	Chemotherapy; Gastric cancer; Chemoradiation; Metastatic; Localized
Core Tip	The standard of care for the management of localized gastric cancer continues to vary depending on where in the world this treatment takes place. In metastatic gastric cancer the outcomes remain poor. The first line treatment consists of trastuzumab in addition to chemotherapy in Her2 positive disease or fluoropyrimidine and platinum (with or without docetaxel or epirubicin) in Her2 negative disease. What is now clear is that second line chemotherapy, with either irinotecan, docetaxel or ramucirumab does improve overall survival.
Publish Date	2014-10-16 15:53
Citation	Elimova E, Shiozaki H, Wadhwa R, Sudo K, Chen Q, Estrella JS, Blum MA, Badgwell B, Das P, Song S, Ajani JA. Medical management of gastric cancer: A 2014 update. World J Gastroenterol 2014; 20(38): 13637-13647
URL	http://www.wjgnet.com/1007-9327/full/v20/i38/13637.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i38.13637

Full Article (PDF)	WJG-20-13637.pdf
Full Article (Word)	WJG-20-13637.doc
Manuscript File	8261-Review.docx
Answering Reviewers	8261-Answering reviewers.pdf
Copyright License Agreement	8261-Copyright assignment.pdf
Peer-review Report	8261-Peer review.pdf
Scientific Editor Work List	8261-Scientific editor work list.pdf